



Symic Bio to Present at the Ladenburg Thalmann 2017 Annual Healthcare Conference

SAN FRANCISCO, Sept. 18, 2017 – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the Ladenburg Thalmann 2017 Healthcare Conference in New York.

Presentation details are as follows:

Date: Tuesday, Sept. 26, 2017
Time: 11 a.m. EDT
Location: Sofitel New York Hotel, New York

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vascular disease, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com